The company had produced the affected lot at its Baddi plant and later marketed in the US market by Macleods Pharma USA Inc.

Pharma firm Zydus Cadila today said it has received final approvals from the US health regulator to market four generic products in America.

According to FDA, "Class-III" classification which was described as "a situation in which use of or exposure to a violative product is not ...